Patents Examined by Hope A. Robinson
  • Patent number: 9920323
    Abstract: The present invention relates to a genetically modified phage and use thereof in a method for producing a biomolecule of interest.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: March 20, 2018
    Inventor: Cedric Szpirer
  • Patent number: 9920337
    Abstract: The present technology relates to novel methods for converting algal biomass material for the production of carbon-based chemicals, in particular carboxylic acids like lactic acid using extremely thermophilic microorganisms.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: March 20, 2018
    Assignee: DIREVO Industrial Biotechnology GmbH
    Inventors: Marco Kramer, Klaudija Milos
  • Patent number: 9920309
    Abstract: The present invention is directed to an enzyme-composition for hydrolyzing biomass containing comprising at least one cellulase, at least one hemicellulases and/or at least one pectinases. In a further aspect, the present invention is directed to a process for hydrolyzing biomass implementing this enzyme-composition and the use of the enzyme-composition for hydrolyzing biomass.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: March 20, 2018
    Inventors: Christoph Reisinger, Lutz Roecher, Michael Kraus, Christian Gamauf
  • Patent number: 9920311
    Abstract: Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: March 20, 2018
    Assignee: Jazz Pharmaceuticals II SAS
    Inventor: Thierry Abribat
  • Patent number: 9920345
    Abstract: Methods of processing lignocellulosic biomass to fermentable sugars are provided which rely on hydrothermal pretreatment. Soft lignocellulosic biomass feedstock is pretreated in a single-stage pressurized hydrothermal pretreatment to very low severity. The pre-treated biomass is hydrolysed, typically as a whole slurry, using enzymatic hydrolysis catalysed by an enzyme mixture comprising endoglucanase, exoglucanase, ?-glucosidase, endoxylanase, and ?-xylosidase activities at activity levels in nkat/g glucan of endoglucanase of at least 1100, exoglucanase of at least 280, ?-glucosidase of at least 3000, endoxylanase of at least 1400, and ?-xylosidase of at least 75, so as to produce a hydrolysate in which the yield of C5 monomers is at least 55% of the original xylose and arabinose content of the feedstock prior to pretreatment.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: March 20, 2018
    Assignee: INBICON A/S
    Inventors: Jan Larsen, Niels Nielsen Poulsen, Martin Dan Jeppesen, Kit Kellebjerg Mogensen
  • Patent number: 9907838
    Abstract: The present disclosure relates to a composition for treating and preventing an ischemic injury. More particularly, it relates to a composition containing a peptide derived from a telomerase, which is effective in treating and preventing an ischemic injury. The peptide according to the present disclosure, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof, has a superior effect of treating and preventing an ischemic injury. Accordingly, a composition containing the peptide may be effectively used for an ischemic injury, particularly for an ischemic-reperfusion injury.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: March 6, 2018
    Assignee: GEMVAX & KAEL CO., LTD.
    Inventor: Sang Jae Kim
  • Patent number: 9896704
    Abstract: The present invention provides a method for producing L-isoleucine by fermentation using a bacterium belonging to the family Enterobacteriaceae which has been modified to overexpress the cycA gene. The method also allows reducing the amount of byproduct amino acids that are produced during fementative production of L-isoleucine using Enterobacteriaceae bacterium having an L-isoleucine-producing ability.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: February 20, 2018
    Assignee: AJINOMOTO CO., INC.
    Inventors: Christina Dmitrievna Hook, Valery Vasilievich Samsonov, Natalia Sergeevna Eremina, Natalia Viktorovna Stoynova, Tatiyana Sergeevna Sidorova
  • Patent number: 9896673
    Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: February 20, 2018
    Assignee: Novozymes A/S
    Inventors: Allan Svendsen, Annette Helle Johansen, Mads Bjoernvad, Frank W. Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • Patent number: 9896716
    Abstract: A method is described for the measurement of thrombin activity in the presence of fibrinogen, or for the measurement of the functionality of fibrinogen in the presence of thrombin.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: February 20, 2018
    Assignees: Ethicon, Inc., Omrix Biopharmaceuticals Ltd.
    Inventors: Roberto Meidler, Anne J. Gorman, Israel Nur, Liliana Bar, Ashley DeAnglis
  • Patent number: 9890367
    Abstract: The present invention provides a novel dual-function lipase variant and its application in processing of flour products. The amino acid sequence of the lipase has one of the following amino acid substitutions: P298T, P298T/H317P, P298T/H317P/V326S, P298T/T218S/S234F, P298T/H317P/P168L/A129S, P298T/S234F/K161R/V326S or the nucleotide sequence of wherein said lipase is substituted, deleted, or added based on the sequence encoding the amino acid described in (a) and has at least 80% identity with it. The variants have good performance in processing of flour products, while they can significantly whiten the bread or other products in processing of flour products and significantly increase the specific volume in bread baking process.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: February 13, 2018
    Assignee: Jiangnan University
    Inventors: Yan Xu, Xiaowei Yu
  • Patent number: 9890373
    Abstract: The present application relates to a modified isoprene synthase that has an isoprene synthetic activity and has at least one mutation of an amino acid residue in the amino acid sequence of SEQ ID NO: 4, an amino acid sequence having one or several amino acid substitutions, deletions, insertions or additions in the amino acid sequence of SEQ ID NO: 4, or an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 4. The modified isoprene synthase is useful for preparing isoprene monomers in improved yields.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: February 13, 2018
    Assignee: Ajinomoto Co., Inc.
    Inventors: Kunio Nakata, Yoshinori Tajima, Uno Tagami, Takashi Oku, Yasuhiro Kashima
  • Patent number: 9879296
    Abstract: The present invention relates to a method for preparing tagatose from residue after extracting coffee, comprising: obtaining a hydrolysate by hydrolyzing residue after extracting coffee into acid; obtaining a hydrolysate refined by decolorization and ion-refining the obtained hydrolysate; and obtaining tagatose by isomerizing the refined hydrolysate to an arabinose isomerase.
    Type: Grant
    Filed: November 27, 2014
    Date of Patent: January 30, 2018
    Inventors: Young Mi Lee, Seong Bo Kim, Min Hae Kim, Sung Jae Yang, Seung Won Park
  • Patent number: 9868963
    Abstract: Disclosed are methods for forming ammonia and ammonium that can be utilized in certifiably organic farming productions according to most if not all known certification standards. Also disclosed are bioreactors that can be utilized in carrying out disclosed methods. Methods and systems utilize obligate anaerobic bacteria to breakdown organic protein substrates, i.e., compounds containing bound nitrogen, to provide nitrogen in an unbound plant available form, and particularly, ammonia and/or ammonium. Obligate anaerobic bacteria include high ammonia producing bacteria such as Peptostreptococcus anaerobius, Clostridium sticklandii, and Clostridium aminophilum.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: January 16, 2018
    Assignee: Clemson University
    Inventor: Brian Keith Ward
  • Patent number: 9856437
    Abstract: The present invention relates to variants (mutants) of polypeptides, in particular Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits an alteration in at least one of the following properties relative to said parent alpha-amylase: substrate specificity, substrate binding, substrate cleavage pattern, thermal stability, pH/activity profile, pH/stability profile, stability towards oxidation, Ca2+ dependency, specific activity, and solubility, in particular under production conditions.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: January 2, 2018
    Assignee: NOVOZYMES A/S
    Inventors: Carsten Andersen, Torben Vedel Borchert, Bjarne Ronfeldt Nielsen
  • Patent number: 9849162
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: December 26, 2017
    Assignee: ALBUMEDIX A/S
    Inventors: David J. Ballance, Darrell Sleep
  • Patent number: 9845513
    Abstract: This invention relates to the production of chemicals by fermentation with a microorganism in which the fermentation medium contains the sugar sucrose. As a specific example, succinic acid is produced from a sucrose-containing renewable feedstock through fermentation using a biocatalyst. Examples of such a biocatalyst include microorganisms that have been enhanced in their ability to utilize sucrose as a carbon and energy source. The biocatalysts of the present invention are derived from the genetic manipulation of parental strains that were originally constructed with the goal to produce one or more chemicals (for example succinic acid and/or a salt of succinic acid) at a commercial scale using feedstocks other than sucrose. The genetic manipulations of the present invention involve the introduction of exogenous genes involved in the transport and metabolism of sucrose into the parental strains.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: December 19, 2017
    Assignee: Myriant Corporation
    Inventors: Sudhandshu Dole, R. Rogers Yocum, Theron Hermann, Xiaohui Yu
  • Patent number: 9840696
    Abstract: The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or RSDs). Furthermore, applications of these transposase variants, the transposon, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 12, 2017
    Assignee: Max-Delbruck-Centrum Fur Molekulare Medizin
    Inventors: Zsuzsanna Izsvak, Zoltan Ivics, Lajos Mates, Namitha Manoj, Carmen-Anisia Judis, Andrea Katzer
  • Patent number: 9834803
    Abstract: This disclosure relates to methods of isolating CDs. The method includes contacting a CD production mixture containing ?CD, ?CD, ?CD, and CD production byproducts with a metal salt; and forming CD-MOF complexes containing at least a metal cation and a plurality of CD components.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: December 5, 2017
    Assignee: PanaceaNano, Inc.
    Inventors: Benjie N. Limketkai, Youssry Y. Botros
  • Patent number: 9834584
    Abstract: Nucleic acid compositions encoding chromo/fluoroproteins and mutants thereof, as well as the encoded proteins, are provided. The subject proteins of interest are proteins that are colored and/or fluorescent, where this feature arises from the interaction of two or more residues of the protein. Also of interest are proteins that are substantially similar to, or mutants of, the above specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms. The subject protein and nucleic acid compositions find use in a variety of different applications. Finally, kits for use in such applications, e.g., that include the subject nucleic acid compositions, are provided.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: December 5, 2017
    Assignee: Takara Bio USA, Inc.
    Inventors: Sergey A. Lukyanov, Arcady F. Fradkov, Yulii A. Labas, Mikhail V. Matz, Alexey Terskikh
  • Patent number: 9834585
    Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of the complement inhibitors in the treatment and prevention of diseases.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: December 5, 2017
    Assignee: Volution Immuni Pharmaceuticals SA
    Inventor: Miles Andrew Nunn